Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M. Ford

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
DNA Repair|May 10, 2015
BRCA1: Beyond double-strand break repairElizabeth Alli, James M Ford
Cancer Journal (Sudbury, Mass.)|August 1, 2012
Genetic testing by cancer site: stomachNicki Chun, James M Ford
Nature Genetics|August 27, 2002
BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repairAnne-Renee Hartman, James M Ford
Clinical Breast Cancer|July 1, 2010
Novel treatment approaches for triple-negative breast cancerMelinda L Telli, James M Ford
Clinical Advances in Hematology & Oncology : H&O|December 16, 2010
PARP inhibitors in breast cancerMelinda L Telli, James M Ford
Journal of Molecular Medicine (Berlin, Germany)|September 19, 2003
BRCA1 and p53: compensatory roles in DNA repairAnne-Renee Hartman, James M Ford
Cancer Research|August 28, 2010
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatinKedar Hastak, Elizabeth Alli, James M Ford
Scientific Reports|October 21, 2025
PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSamyuktha Suresh, Lisa McPherson, James M Ford
Cancer Letters|November 13, 2013
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cellsLisa A McPherson, Yuqiao Shen, James M Ford
Oncotarget|April 17, 2017
Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancersKedar Hastak, Steven Bhutra, Renate Parry, et al.
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
DNA Repair|May 10, 2015
BRCA1: Beyond double-strand break repairElizabeth Alli, James M Ford
Cancer Journal (Sudbury, Mass.)|August 1, 2012
Genetic testing by cancer site: stomachNicki Chun, James M Ford
Nature Genetics|August 27, 2002
BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repairAnne-Renee Hartman, James M Ford
Clinical Breast Cancer|July 1, 2010
Novel treatment approaches for triple-negative breast cancerMelinda L Telli, James M Ford
Clinical Advances in Hematology & Oncology : H&O|December 16, 2010
PARP inhibitors in breast cancerMelinda L Telli, James M Ford
Journal of Molecular Medicine (Berlin, Germany)|September 19, 2003
BRCA1 and p53: compensatory roles in DNA repairAnne-Renee Hartman, James M Ford
Cancer Research|August 28, 2010
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatinKedar Hastak, Elizabeth Alli, James M Ford
Scientific Reports|October 21, 2025
PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSamyuktha Suresh, Lisa McPherson, James M Ford
Cancer Letters|November 13, 2013
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cellsLisa A McPherson, Yuqiao Shen, James M Ford
Oncotarget|April 17, 2017
Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancersKedar Hastak, Steven Bhutra, Renate Parry, et al.
Pageof 18